# A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

> **NCT01292603** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 240 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** rituximab [MabThera]
- **DRUG:** rituximab [MabThera]
- **DRUG:** rituximab [MabThera]

## Key facts

- **NCT ID:** NCT01292603
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-18
- **Primary completion:** 2014-05-07
- **Final completion:** 2017-11-17
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01292603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01292603, "A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01292603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*